# RAG-Based ASCO-Style Scorecards (PubMed Context Only, LanceDB)

## Scorecard for: Enzalutamide Versus Placebo After Chemotherapy in Metastatic Adenocarcinoma of Prostate

**Scenario Hint Provided to LLM:** A trial of enzalutamide vs placebo in metastatic prostate cancer post-chemotherapy. Hypothesize plausible efficacy (OS/PFS) and common toxicities for this drug class in this setting. Consider potential for some bonus points.

Below is a hypothetical ASCO Value Framework scorecard for the trial “Enzalutamide Versus Placebo After Chemotherapy in Metastatic Adenocarcinoma of Prostate” based on plausible inputs:

• Hypothesized primary endpoint benefit: An overall hazard ratio (HR) of 0.75 was chosen. This implies that treatment with enzalutamide results in about a 25% reduction in the risk of an event relative to placebo. This magnitude of benefit is consistent with an incremental, yet clinically meaningful survival/PFS benefit in the post‐chemotherapy mCRPC setting.

• Hypothesized toxicity: Although enzalutamide generally is well tolerated, compared with placebo a modest increase in grade ≥3 toxicities (such as fatigue, hypertension, or rare seizures) may be observed. Based on this, we assign a toxicity penalty of –5 points.

• Hypothesized bonus points:
  – Tail of the Curve: Many patients with mCRPC derive durable benefit on enzalutamide, so we assign 10 bonus points.
  – Palliation: Enzalutamide has been shown to improve symptoms and maintain quality of life, warranting 5 bonus points.
  – Treatment-Free Interval: In a post-chemotherapy setting, extending the interval before a new therapy is needed provides additional value; assign 3 bonus points.
  – Health-related Quality of Life (HRQoL): Improvement or maintenance of HRQoL gives a further 5 bonus points.
  Total bonus points sum to 23.

• Cost: Based on the class and typical US pricing of androgen receptor inhibitors in mCRPC, we hypothesize a cost of $12,000 per month.

Below is the formatted scorecard table:

--------------------------------------------------
| Measure                     | Result/Score                                                            |
|-----------------------------|-------------------------------------------------------------------------|
| **Clinical Benefit Score**  | (1 – 0.75) * 100 * 1 = 25                                               |
| **Toxicity Score**          | Modest increase in grade ≥3 events vs placebo → –5                      |
| **Bonus Points**            | Tail of the Curve: 10                                                   |
|                             | Palliation: 5                                                           |
|                             | Treatment-Free Interval: 3                                              |
|                             | Health-related QoL: 5                                                   |
| **Total Bonus Points**      | 10 + 5 + 3 + 5 = 23                                                     |
| **Net Health Benefit**      | 25 + (–5) + 23 = 43                                                     |
| **Cost**                   | $12,000 per month                                                       |
--------------------------------------------------

This scorecard is entirely hypothetical and based on reasonable assumptions regarding the efficacy, toxicity, bonus metrics, and cost typical for enzalutamide in the post-chemotherapy mCRPC setting.

---

## Scorecard for: Doxorubicin + Cyclophosphamide → Paclitaxel + Trastuzumab vs Doxorubicin + Cyclophosphamide + Paclitaxel in Adjuvant HER2+ Breast Cancer

**Scenario Hint Provided to LLM:** A trial comparing a trastuzumab-containing regimen (AC-TH type) with a non-trastuzumab chemo regimen (AC-T type) in adjuvant HER2+ breast cancer. Hypothesize impact of targeted therapy on efficacy. Toxicity might be similar or specific to trastuzumab.

Below is one plausible ASCO Value Framework–style scorecard based on hypothesized inputs for this trial:

• Hypothesized Hazard Ratio for the primary endpoint: 0.70. This reflects a solid, targeted-efficacy improvement with the addition of trastuzumab relative to standard AC-T like therapy. Using (1 – HR)*100 (with Factor = 1) gives a clinical benefit score of 30.  
• Hypothesized toxicity: While overall chemo-related toxicities are similar between arms, the experimental arm with trastuzumab may have a slightly higher risk of cardiac toxicity. This has been assigned a modest penalty of –3 points.  
• Hypothesized bonus points:  
  – Tail of the Curve: A potential long-term survival benefit with trastuzumab in HER2+ patients gives 10 bonus points.  
  – Palliation: In an adjuvant setting where cure is intended, palliation is less relevant (0 points).  
  – Treatment-Free Interval: Improved disease control allowing for a longer period off therapy is modestly beneficial (+5 points).  
  – Health-related Quality-of-Life: Some advantage is anticipated due to more effective disease control and manageable toxicity (+3 points).  
 The total bonus points sum to 18.  
• Hypothesized cost: Given that trastuzumab-containing regimens are high-cost targeted therapies, a plausible estimate is "$120,000 total course."

Below is the complete scorecard table:

| Measure                      | Result/Score                                                                                     |
|------------------------------|--------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score**   | (1 – 0.70) * 100 * 1 = **30**                                                                     |
| **Toxicity Score**           | Slight increase in cardiac toxicity in experimental arm: **–3**                                   |
| **Bonus Points**             | Tail of the Curve: 10 points                                                                     |
|                              | Palliation: 0 points                                                                             |
|                              | Treatment-Free Interval: 5 points                                                                |
|                              | Health-related QoL: 3 points                                                                     |
| **Total Bonus Points**       | 10 + 0 + 5 + 3 = **18**                                                                          |
| **Net Health Benefit**       | Clinical Benefit (30) + Toxicity (–3) + Bonus Points (18) = **45**                                 |
| **Cost (Total Course)**      | **$120,000 total course**                                                                        |

This scorecard is based on the hypothesized estimates and serves as one plausible interpretation of the impact of adding trastuzumab to the adjuvant regimen in HER2+ breast cancer.

---

## Scorecard for: Ipilimumab Versus Placebo After Primary Treatment of Stage III Melanoma

**Scenario Hint Provided to LLM:** A trial of ipilimumab vs placebo in the adjuvant setting for Stage III melanoma. Hypothesize plausible DFS benefit and significant immune-related toxicities common for older checkpoint inhibitors.

Below is one plausible ASCO Value Framework style scorecard for the trial “Ipilimumab Versus Placebo After Primary Treatment of Stage III Melanoma.” Remember that the following values are hypothetical estimates based on general expectations for adjuvant ipilimumab in melanoma and the common immune‐related toxicities seen with older checkpoint inhibitors.

• Hypothesized primary endpoint benefit: Assume a hazard ratio (HR) for disease‐free survival of 0.70. This HR suggests a 30% relative reduction in the risk of DFS events compared to placebo—a moderate DFS benefit in the adjuvant setting.

• Hypothesized toxicity metrics: Ipilimumab is known to cause significant immune-related toxicities compared with placebo. In our estimation, these toxicities warrant a moderate penalty (–10 points) to reflect the risk of immune-related adverse events.

• Hypothesized Bonus Points:  
  – Tail of the Curve: Award 10 bonus points based on the potential for long‐term durable responses seen in subsets of patients.  
  – Treatment-Free Interval: Award 4 bonus points because patients who finish adjuvant therapy and remain disease–free may enjoy a period off treatment.  
  – Palliation and Health-related Quality of Life: In the adjuvant setting—with curative intent rather than symptom palliation—no bonus is given (0 points).  
Total bonus points = 10 + 4 + 0 + 0 = 14.

• Hypothesized Cost: Given that ipilimumab is an older checkpoint inhibitor with established high cost, assume a total course cost of $150,000.

• Calculations:  
 Clinical Benefit Score = (1 – HR) * 100 * Factor = (1 – 0.70)*100 = 30.  
 Net Health Benefit (NHB) = Clinical Benefit Score + Toxicity Score + Total Bonus Points = 30 + (–10) + 14 = 34.

Below is the corresponding scorecard table:

--------------------------------------------------------------
| Measure                     | Result/Score                                                                                  |
|-----------------------------|-----------------------------------------------------------------------------------------------|
| **Clinical Benefit Score**  | (1 – 0.70) * 100 * 1 = **30**                                                                  |
| **Toxicity Score**          | Significant immune-related toxicities vs placebo → **–10**                                     |
| **Bonus Points**            | Tail of the Curve: 10                                                                        |
|                             | Palliation: 0                                                                                |
|                             | Treatment-Free Interval: 4                                                                   |
|                             | Health-related QoL: 0                                                                        |
| **Total Bonus Points**      | 10 + 0 + 4 + 0 = **14**                                                                        |
| **Net Health Benefit**      | 30 (Clinical Benefit) + (–10) (Toxicity) + 14 (Bonus) = **34**                                 |
| **Cost**                    | $150,000 total course                                                                        |
--------------------------------------------------------------

This hypothetical scorecard reflects a moderate DFS benefit, significant immune-related toxicity challenges, and some bonus points due to potential long-term durability and treatment interruption advantages.

---

## Scorecard for: Ibrutinib Versus Chlorambucil As Initial Therapy for Chronic Lymphocytic Leukemia

**Scenario Hint Provided to LLM:** A trial comparing ibrutinib (newer targeted therapy) against chlorambucil (older chemotherapy) as first-line treatment for CLL. Hypothesize significant efficacy benefit for ibrutinib but also its unique toxicity profile versus chlorambucil.

Below is one plausible ASCO Value Framework–style scorecard based on a hypothesized assessment of the trial results for ibrutinib versus chlorambucil in front‐line CLL.

Hypothesized inputs and rationale:  
• Primary endpoint: Assume the use of a progression-related endpoint with an HR of 0.55 for ibrutinib compared with chlorambucil. This represents a practice-changing, substantial improvement (a 45% relative reduction in risk).  

• Toxicity: Although ibrutinib delivers significant efficacy benefits, it is known to have unique toxicities (for example, atrial fibrillation and hypertension) that are more concerning than the relatively milder side effects with chlorambucil. We assign a moderate toxicity penalty of –8 points.  

• Bonus Points:  
 – Tail of the Curve: Improved long-term outcomes with ibrutinib justify awarding a 10-point bonus.  
 – Palliation: Improved symptom control compared with chemotherapy merits a 5-point bonus.  
 – Treatment-Free Interval: Delayed need for subsequent therapy with targeted agents earns a 5-point bonus.  
 – Health-Related QoL: A potentially better quality-of-life profile with a targeted agent is worth another 5 points.  
   Total Bonus Points = 10 + 5 + 5 + 5 = 25.  

• Cost: For a novel, targeted agent such as ibrutinib, a plausible hypothesized cost might be around $15,000 per month.

Using these inputs, we calculate each component as follows:

• Clinical Benefit Score = (1 – HR) * 100 * Factor = (1 – 0.55) * 100 * 1 = 45.  
• Toxicity Score = –8 (reflecting a moderate penalty for increased cardiovascular toxicity risks).  
• Total Bonus Points = 25.  
• Net Health Benefit (NHB) = Clinical Benefit Score + Toxicity Score + Total Bonus Points = 45 + (–8) + 25 = 62.

Below is the scorecard table summarizing these assessments:

-------------------------------------------------
| Measure                  | Result/Score                                                         |
|--------------------------|----------------------------------------------------------------------|
| **Clinical Benefit Score** | (1 – 0.55) * 100 * 1 = **45**                                       |
| **Toxicity Score**        | Increased cardiovascular toxicity (e.g., AF, HTN) relative to chlorambucil: **–8** |
| **Bonus Points**          | Tail of the Curve: **10**                                            |
|                          | Palliation: **5**                                                    |
|                          | Treatment-Free Interval: **5**                                       |
|                          | Health-related QoL: **5**                                            |
| **Total Bonus Points**    | 10 + 5 + 5 + 5 = **25**                                              |
| **Net Health Benefit**    | 45 + (–8) + 25 = **62**                                              |
| **Cost**                  | **$15,000 per month**                                                |
-------------------------------------------------

This hypothetical scorecard reflects a significant clinical benefit (45 points) with some toxicity penalty (–8 points), which is partially offset by bonus points (25 points) for improved long-term outcomes, symptomatic relief, extended treatment-free intervals, and quality-of-life measures, resulting in a net health benefit of 62. The estimated cost context is approximately $15,000 per month for the novel targeted therapy.

---

